Associated Papers
Locus-specific transcriptional regulation of transposable elements by p53.
Freewoman JM et al.
Cell Cycle (georgetown, Tex.), 2026
TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study.
Zhang H et al.
Annals of Hematology, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
Carboplatin monotherapy in recurrent uterine leiomyosarcoma with homozygous BRCA2 deletion: a case report.
Ujihira T et al.
International Cancer Conference Journal, 2026
Pathogenic Proteins Through the Lens of NMR Spectroscopy: Structural and Functional Insights into Disease.
Aboalroub AA
Cell Biochemistry and Biophysics, 2025
Somatic Mutation Profiling and Therapeutic Landscape of Breast Cancer in the MENA Region.
Velayutham D et al.
Cells, 2025
Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition.
Liu K et al.
Communications Biology, 2025
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review.
Abujamous L et al.
The Oncologist, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Waldenström Macroglobulinemia: The Role of TP53 Mutations in Disease Progression and Therapeutic Response.
Kampitsi DD et al.
Current Issues in Molecular Biology, 2025
The Interconnection Between UbcH10, p53, and EGFR in Lung Cancer Cells and Their Involvement in Treatment Response.
Quintavalle C et al.
Genes, 2025
The key vulnerabilities and therapeutic opportunities in the USP7-p53/MDM2 axis in cancer.
Saha G et al.
Biochimica Et Biophysica Acta. Molecular Cell Research, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Richters L et al.
Jama Network Open, 2025
TP53: the unluckiest of genes?
Joerger AC et al.
Cell Death and Differentiation, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
Genetic heterogeneity and key driver mutations in the preneoplastic and earliest stages of gastric cancer.
Marroquín-Estrada EA et al.
Gastroenterology Report, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
GRAIL1 Stabilizes Misfolded Mutant p53 through a Ubiquitin Ligase-Independent, Chaperone Regulatory Function.
Ray P et al.
Molecular Cancer Research : Mcr, 2024
Changes in TP53 Gene, Telomere Length, and Mitochondrial DNA in Benign Prostatic Hyperplasia Patients.
Zole E et al.
Biomedicines, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Sudhakar N et al.
Molecular Cancer Therapeutics, 2024
Thermal stress, p53 structures and learning from elephants.
Karakostis K et al.
Cell Death Discovery, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
TP53 mutation screening for patients at risk of myeloid malignancy.
Mukherjee D et al.
Leukemia, 2024
The Strong Activation of p53 Tumor Suppressor Drives the Synthesis of the Enigmatic Isoform of DUSP13 Protein.
Krześniak M et al.
Biomedicines, 2024
The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients.
Vasseur D et al.
Npj Precision Oncology, 2024
TP53 mutation screening for patients at risk of myeloid malignancy.
Mukherjee D et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
A new genomic framework to categorize pediatric acute myeloid leukemia.
Umeda M et al.
Nature Genetics, 2024
DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors.
Folly-Kossi H et al.
Cancer Research Communications, 2023
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
Tsantikidi A et al.
Diagnostics (basel, Switzerland), 2023
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression.
Chang YC et al.
Cancer Letters, 2023
Molecular dynamics simulations suggest Thiosemicarbazones can bind p53 cancer mutant R175H.
Das T et al.
Biochimica Et Biophysica Acta. Proteins and Proteomics, 2023
RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer.
Jbara A et al.
Nature, 2023
Disease-related p63 DBD mutations impair DNA binding by distinct mechanisms and varying degree.
Osterburg C et al.
Cell Death & Disease, 2023
Evaluating the prognostic significance of p53 and TP53 mutations in HPV-negative hypopharyngeal carcinoma patients: a 5-year follow-up retrospective study.
Huang Q et al.
Bmc Cancer, 2023